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CTLs	eliminate	virus-infected	and	tumorigenic	cells	through	exocytosis	of	cytotoxic	agents	from	lytic	granules.	
While	insights	into	the	intracellular	mechanisms	facilitating	lytic	granule	release	have	been	obtained	through	
analysis	of	loss-of-function	mutations	in	humans	and	mice,	there	is	a	paucity	of	information	on	negative	
regulators	of	secretory	lysosome	release	at	the	molecular	level.	By	generating	and	analyzing	estrogen	recep-
tor–binding	fragment-associated	antigen	9–KO	(Ebag9	KO)	mice,	we	show	here	that	loss	of	EBAG9	confers	
CTLs	with	enhanced	cytolytic	capacity	in	vitro	and	in	vivo.	Although	loss	of	EBAG9	did	not	affect	lymphocyte	
development,	it	led	to	an	increase	in	CTL	secretion	of	granzyme	A,	a	marker	of	lytic	granules.	This	resulted	
in	increased	cytotoxicity	in	vitro	and	an	enhanced	cytolytic	primary	and	memory	T	cell	response	in	vivo.	We	
further	found	that	EBAG9	interacts	with	the	adaptor	molecule	γ2-adaptin,	suggesting	EBAG9	is	involved	in	
endosomal-lysosomal	biogenesis	and	membrane	fusion.	Indeed,	granzyme	B	was	sorted	to	secretory	lysosomes	
more	efficiently	in	EBAG9-deficient	CTLs	than	it	was	in	WT	CTLs,	a	finding	consistent	with	the	observed	
enhanced	kinetics	of	cathepsin	D	proteolytic	processing.	While	EBAG9	deficiency	did	not	disrupt	the	forma-
tion	of	the	immunological	synapse,	lytic	granules	in	Ebag9–/–	CTLs	were	smaller	than	in	WT	CTLs.	These	data	
suggest	that	EBAG9	is	a	tunable	inhibitor	of	CTL-mediated	adaptive	immune	response	functions.
Introduction
CTLs and NK cells employ regulated exocytosis of perforin and 
granzymes, cytotoxic agents from specialized secretory lysosomes 
(also referred to as lytic granules) to eliminate virus-infected and 
tumorigenic transformed cells (1). While genetic experiments 
with gene-deleted mice or in T cells derived from patients with 
hereditary diseases have provided most of the current evidence for 
the consequences of a loss-of-function mutation in the adaptive 
immune response, the characterization of negative regulators in 
CTL function has thus far received little attention (2–4).
To maintain cytolytic effector functions in CTLs, a constant sup-
ply with newly synthesized or recycled effector molecules has to be 
ensured. The delivery of newly synthesized acid hydrolase precur-
sors, among them granzymes and cathepsins, beyond the Golgi 
complex depends on the association of these enzymes with the 
mannose 6-phosphate receptor (M6PR) (5). This complex recruits 
clathrin adaptors, followed by the formation of clathrin-coated 
vesicles or carriers that transport the hydrolase-M6PR complex 
to endosomes. After dissociation of the complex in endosomes, 
the hydrolase is targeted to lysosomes, while the receptor recycles 
to the trans-Golgi network (TGN). Sorting of such complexes at 
the TGN is intimately linked with the function of multi-compo-
nent adaptor protein complexes 1–4 (AP1–4) and members of the 
monomeric Golgi-localized, γ-ear–containing ADP-ribosylation 
factor–binding (ARF-binding) protein (GGA) family of adaptors 
(6). Selective transport of cargo proteins from the TGN to endo-
somes is under the control of the ubiquitously expressed AP1 com-
plex and monomeric GGA adaptor proteins. Based on the homol-
ogy to the large subunit of AP1, γ1-adaptin, the isoform γ2-adaptin 
has been previously described (7–9). γ2-Adaptin appears to func-
tion independently of AP1 and γ1-adaptin, and major differences 
include subcellular localization, lack of dependency on the GTPase 
ARF1 for recruitment onto TGN membranes, and the inability of 
γ2-adaptin to substitute for the loss of γ1-adaptin in gene-deleted 
mice (7–9). Thus, γ2-adaptin may not act as a typical vesicle-form-
ing adaptor, and γ2-adaptin–containing AP complexes have not 
yet been identified. While information on the physiological role of 
γ2-adaptin is rare, support for a sorting function within the endo-
somal-lysosomal compartment came from an infection model in 
which γ2-adaptin controlled hepatitis B virus (HBV) production 
and virion secretion (10, 11).
We previously reported that the tumor-associated anti-
gen estrogen receptor–binding fragment-associated antigen 9 
(EBAG9), upon overexpression in PC12 cells, imposed an inhibi-
tory effect on synaptic-like vesicle release (12). In these neuroen-
docrine cells EBAG9, also referred to as receptor binding cancer 
antigen expressed on SiSo cells (RCAS1), was shown to interact 
with Snapin, an enhancer of synaptic vesicle priming which acts 
through recruitment of synaptotagmin I to the synaptic soluble 
N-ethylmaleimide–sensitive factor attachment protein receptor 
(SNARE) complex (13). According to the SNARE hypothesis, tar-
get and vesicle SNAREs form a core complex that brings vesicle and 
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target membrane together, ultimately leading to membrane fusion 
(2, 14–16). In addition to this vesicle-priming step in neurons, a 
second function for Snapin in exocytosis has been suggested, 
as Snapin was described to be a member of the biogenesis of lyso-
some-related organelles complex-1 (BLOC-1) (17).
EBAG9 overexpression was previously recorded in several carci-
noma entities, and accordingly this molecule has been suggested to 
be an independent prognostic marker for disease-specific survival 
(18–20). However, its broad tissue distribution, and occurrence in 
benign tissues at all developmental stages make it unlikely that the 
molecule has evolved for tumor immune escape only, as had been 
initially suggested (20, 21). Protein expression of EBAG9 is estrogen 
inducible and has been shown in cell lines and in estrogen-treated 
mice (22–24). In general, the physiological pleiotropic effects of 
estrogens are well known in many aspects of development, but 
their effector mechanisms at the molecular level and their potential 
pathogenic effects on immunity are not fully understood (25, 26).
To resolve the functional relevance of Ebag9 in vivo, we devel-
oped a gene-deleted mouse strain. In this model, we revealed a 
physiological immunoregulatory function of EBAG9. We focused 
on CTL equipped with secretory lysosomes that undergo polarized 
transport and exocytosis in a Ca2+-dependent manner (27). Loss of 
EBAG9 amplified release of lytic granule content and facilitated 
enhanced cytolytic capacity in vitro and in vivo. We identified what 
we believe is a novel interaction partner of EBAG9, γ2-adaptin, 
which suggests that EBAG9 is required for the control of the endo-
somal-lysosomal trafficking route in cytotoxic T cells. These data 
define a critical role for EBAG9 as an estrogen-responsive repressor 
of T cell cytolytic capacity during adaptive immune responses.
Results
Generation of EBAG9-deficient mice. To study the physiological func-
tion of EBAG9, we generated Ebag9-deficient mice by homologous 
recombination in ES cells (Figure 1A). The deleted region con-
tained the translation start site as well as exons 2–4, encoding aa 
1–107. Southern blot hybridization verified the homologous 
recombination event, yielding the expected fragment of approxi-
mately 4.5 kb in mutant genomic DNA (Figure 1B). Western blot 
analysis of lymph node lysates confirmed the absence of EBAG9 
protein in homozygous mutant mice (Figure 1C). Ebag9–/– mice 
were healthy and fertile without any apparent morphological 
abnormalities. In the C57BL/6 strain background, animals exhib-
ited a black coat color. Analysis of genotypes at weaning revealed 
that the mutated allele segregated at a normal Mendelian frequency 
of Ebag9+/+ (25%), Ebag9+/– (50%), and Ebag9–/– (25%) mice (matings, 
n > 20). Additionally, matings of EBAG9-deficient mice produced 
normal litters, which strongly argues against a postulated role of 
EBAG9 in maintaining pregnancy at early stages of embryonic 
development by downregulation of the maternal immune response 
(28). Furthermore, EBAG9 was suggested to regulate erythroid 
development by modulating apoptosis of erythroid progenitor cells 
(29). However, EBAG9-deficient mice exhibited normal peripheral 
blood cell counts and erythroid progenitors (Ter119+CD71+) in 
the bone marrow were unaltered (Supplemental Table 1; supple-
mental material available online with this article; doi:10.1172/
JCI37760DS1). Development of lymphocytes from secondary lym-
phoid organs was not affected by the EBAG9 mutation because 
gene-deleted mice displayed comparable numbers (data not shown) 
and subsets of lymphocytes (Supplemental Table 2).
In immunoblot analysis a broad tissue distribution of EBAG9 
(from WT mice) was obtained, among them lymphoid organs (Fig-
ure 1D). Ex vivo cultures from WT animals showed that EBAG9 
protein was expressed in CTLs and NK cells (Figure 1E). In this 
study, we focused on CTLs and NK cells, since their regulated 
secretory pathway used for the release of cytotoxic mediators from 
lytic granules exhibits extensive mechanistic analogy to the neuro-
endocrine cell system (2).
Deletion of Ebag9 leads to an enhanced release of granzyme A from CTLs, 
resulting in an increased cytotoxicity in vitro. To investigate the role of 
Figure 1
Generation of Ebag9 mutant mice. (A) Schematic representation of 
the targeting strategy employed to disrupt the Ebag9 gene. The WT 
Ebag9 locus (top), the targeting vector (middle), and the mutated locus 
(Ebag9Δ) after homologous recombination (bottom) are shown. The 
Ebag9 gene consists of 7 exons; exons removed after homologous 
recombination are shown in red. The predicted fragment sizes after 
XhoI (X) and BamHI (B) digestion of genomic DNA are indicated. Neo, 
neomycin resistance cassette; Tk, thymidine kinase cassette. (B) 
Southern blot analysis of XhoI/BamHI-digested genomic DNA from F1 
animals using the probe indicated in A. (C) Western blot analysis of 
EBAG9 expression in lymph nodes from adult mice, using polyclonal 
anti-EBAG9 serum. (D) Differential expression of the EBAG9 protein 
in various tissues analyzed by immunoblot. (E) Immunoblot analysis of 
EBAG9 expression in WT CTLs and NK cells.
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EBAG9 in the secretory pathway of CD8+ T cells, we generated CTLs 
from Ebag9+/+ and Ebag9–/– splenocytes (H-2b haplotype) in a mixed 
lymphocyte reaction (MLR). Numbers of CD8+ (88% ± 5%, mean ± SD) 
and CD4+ (3% ± 3%, mean ± SD) T cells obtained were comparable 
between Ebag9–/– and Ebag9+/+ animals (n = 7 experiments; data not 
shown). Induced secretion of the lytic granule marker granzyme A 
from EBAG9-deficient CTLs was significantly increased compared 
with WT (45%) (Figure 2A). Total intracellular enzymatic activity 
of granzyme A in Ebag9+/+ and Ebag9–/– CTLs was comparable (data 
not shown). Flow cytometry analysis revealed a stimulation-depen-
dent increase in the cell surface expression of CTLA4, but a differ-
ence between Ebag9+/+ and Ebag9–/– CTLs was not seen (Figure 2B). 
Likewise, we found no significant differences in the release of IFN-γ 
(Figure 2C), which is rapidly secreted by the constitutive secretory 
pathway after TCR activation (30), or the chemokine RANTES (Sup-
plemental Figure 1), which is released by a mechanism distinct from 
lytic granule exocytosis or IFN-γ secretion (31).
In an allogeneic cytotoxicity 
assay against Fas-negative P815 
target cells (H-2d haplotype) (Fig-
ure 2D), Ebag9–/– CTLs exhibited a 
profound advantage in target cell 
lysis, visible as a 3-fold increase in 
lytic potency at lower effector to 
target ratios. To confirm that the 
enhanced killing capability of 
the EBAG9-deficient CTLs relies 
on the improved release of gran-
zyme-containing lytic granules, 
the allogeneic cytotoxicity assay 
was repeated in the presence of 
lysosomal acidification inhibi-
tor concanamycin A and the 
granzyme B inhibitor Z-AAD-
CMK. In the presence of these 
drugs, Ebag9+/+ and Ebag9–/– CTLs 
showed comparable abilities for 
target cell lysis (Supplemental 
Figure 2). In summary, deletion 
of EBAG9 provides CTLs with 
an enhanced capacity for in vitro 
cytotoxicity.
Enhanced primary and sec-
ondary CD8+ T cell responses in 
EBAG9-deficient mice in vivo. To 
examine the functional signifi-
cance of enhanced lytic granule 
release for primary CD8+ T cell 
responses in vivo, we made use 
of a syngeneic antigen-specific 
SV40 T antigen (Tag) mouse 
model (32). First, we investi-
gated the influence of EBAG9 
deletion on the antigen-spe-
cific elimination of cells loaded 
with the dominant Tag epit-
ope–derived peptide IV in pri-
mary T cell responses. For this 
in vivo kill assay, Ebag9+/+ and 
Ebag9–/– mice were immunized 
with Tag-bearing Co16.113 cells. After 7 days, non-loaded and 
Tag peptide IV–loaded spleen cells were injected into Tag-immu-
nized or control naive WT mice (Figure 3A). Tag peptide IV–
loaded spleen cells were eliminated in Tag-immunized mice, but 
not in naive WT animals. In Ebag9–/– mice the decrease of Tag 
peptide–loaded cells was significantly enhanced, correspond-
ing to an increased killing potency of Ebag9–/– CTLs (Figure 3B) 
(WT, 21.5% ± 10.5%; KO, 53.5% ± 13.6%; mean ± SD). Another 
systemic model to study primary CTL responses in vivo is the 
clearance of the bacterium Listeria monocytogenes. After injection, 
these bacteria migrate to various target organs, including liver, 
where they enter hepatocytes. Ebag9–/– and Ebag9+/+ mice were 
challenged with L. monocytogenes, and the CTL response was ana-
lyzed by determining the bacterial titer in liver 6 days later (Fig-
ure 3C). Significantly lower bacterial titers were obtained from 
Ebag9–/– livers, suggesting that gene-deleted animals exhibited 
an improved CTL-mediated clearance function.
Figure 2
Secretory granule release in CTLs. (A) CTLs were generated in a 3- to 6-day MLR. Release of granzyme A 
from CTLs was induced by cross-linking of the TCR with anti-CD3ε mAb for 4 hours. Enzymatic activity 
in supernatants was determined. Secretion is expressed as percentage of maximal activity, measured 
for Triton X-100 cell lysates. Data are mean ± SD of 7 independent experiments performed in triplicate. 
*P < 0.02, Student’s t test. (B) Cell surface translocation of CTLA4. CTLs were stimulated for 4 hours with 
plate-bound mAbs (anti-CD3ε, 5 μg/ml; anti-CD28, 3 μg/ml) (+CD3) or left untreated (-CD3). Cells were 
stained for CTLA4 and CD8 expression without permeabilization, and viable cells were gated for analysis 
of CTLA4 fluorescence by flow cytometry. One representative example of 6 independent experiments is 
shown. Gray histogram shows the isotype control. (C) Release of IFN-γ upon TCR activation. Superna-
tants from A were analyzed by ELISA. Data are mean ± SD of 6 independent experiments. (D) Cytolytic 
activity of CTLs (H-2b haplotype) at different ratios of effector cells to a fixed number of allogeneic P815 
target cells (H-2d haplotype). Data represent mean ± SD of quadruplicate experiments. One representa-
tive experiment of 8 is shown.
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The occurrence of EBAG9 in the NK cell lineage prompted us to 
compare their cytolytic capacity in Ebag9+/+ and Ebag9–/– animals. 
In an in vivo kill assay against allogeneic target splenocytes, no 
significant difference between WT and mutant mice was observed 
(Figure 3D). Likewise, in a standard NK cell in vitro cytotoxicity 
assay against YAC-1 target cells, the cytolytic capacity between 
both groups was comparable (Figure 3E). To further rule out a 
confounding effect of NK cells in our antigen-specific Tag peptide 
model, we treated recipient EBAG9 mutant mice with anti–IL-2Rβ 
mAb (TM-β1). Depletion of NK cells did not attenuate the mag-
nitude of Tag peptide–loaded target cell elimination, thus sup-
porting our conclusion that EBAG9 plays a significant role in this 
CTL-dependent model in vivo (Supplemental Figure 3).
To investigate CTL activity in secondary T cell responses, Ebag9+/+ 
and Ebag9–/– mice were challenged again after more than 30 days. 
Four days after secondary immunization, the elimination of Tag 
peptide–loaded spleen cells was measured as described above. 
Ebag9–/– mice exhibited a substantially stronger cytolytic memory 
T cell response compared with Ebag9+/+ or naive mice (Figure 3F) 
(WT, 17.1% ± 9.4%; KO, 47% ± 15.57%; mean ± SD). Frequencies of 
antigen-specific CD8+ T cells were assessed using H-2Kb dimers load-
ed with the Tag peptide at day 6 after the second challenge (boost). 
Under these restimulation conditions, no significant differences 
in the frequency of antigen-specific CTLs between WT and KO 
mice were seen (WT, 1.39% ± 0.76%; KO, 1.8% ± 0.93%; mean ± SD; 
P = 0.22, Mann-Whitney test) (Supplemental Figure 4).
Priming and expansion of naive antigen-specific T cells. The enhanced 
cytolytic capacity of EBAG9-deficient T cells could be related to 
the frequency of antigen-specific T cells. As noted before (Supple-
mental Table 2), total numbers and composition of lymphocyte 
subsets in spleen and lymph nodes from WT and KO animals 
were indistinguishable.
The frequency of effector T cells is intimately linked with the 
priming phase, a process in which DCs play a leading role through 
the presentation of antigen and provision of costimulation (33, 
34). When we analyzed the frequencies of antigen-specific CD8+ 
T cells using H-2Kb dimers loaded with the Tag peptide at day 8 
after immunization, no significant differences between KO and 
WT animals were observed (Figure 4A). Frequencies of Tag dimer–
positive T cells in non-immunized Ebag9+/+ and Ebag9–/– were 
indistinguishable. Those results were confirmed by the same fre-
quencies of IFN-γ+CD8+ T cells after immunization (Figure 4B). To 
exclude the possibility that KO CTLs had an inherent proliferative 
advantage, we assessed the proliferation rate of Tag dimer–positive 
Figure 3
Enhanced antigen-specific CD8+ T cell responses in vivo. (A) Immunized (I) WT and KO mice were challenged at day 7 with non-loaded and 
peptide-loaded spleen cells labeled with different amounts of CFSE. The ratio between the 2 populations was determined by flow cytometry 
4 hours later. One representative example of 7 is shown. N, naive non-immunized C57BL/6 mice. (B) Primary CD8+ T cell response. The 
percentage of specific killing of peptide-loaded cells in WT (filled squares) and KO (open triangles) mice is indicated. Shown are combined 
data from 2 independent experiments (n = 7). **P < 0.001, Student’s t test. (C) Ebag9+/+ and Ebag9–/– were infected with L. monocytogenes. 
Bacterial titers (day 6) are indicated. *P < 0.05, Mann-Whitney test. (D) Ebag9+/+ and Ebag9–/– (H-2b haplotype) mice were inoculated i.v. with 
CFSE-labeled H-2d and H-2b splenocytes. After 4 hours, the ratio between the 2 populations in the spleen was determined. Specific killing 
of allogeneic H-2d splenocytes is indicated. Shown are combined data of 2 independent experiments (n = 5). (E) Cytolytic activity of NK cells 
against a fixed number of YAC-1 cells. Data are mean ± SD of quadruplicate experiments. One representative example of 2 experiments 
is shown. (F) Ebag9+/+ and Ebag9–/– mice were primed as described in A, followed by a boost after 30 days. On day 4 after rechallenge, a 
cytotoxicity assay was performed as described in A. Shown are combined data of 2 independent experiments (n = 7). **P < 0.001, Student’s 
t test. Horizontal bars in B, C, D, and F indicate mean values.
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T cells during a primary immune response (Figure 4, C and D). We 
observed an identical proliferation rate of Tag dimer– and IFN-γ– 
positive CD8+ T cells, as determined by BrdU uptake.
DCs are considered the most potent APC subpopulation, as 
they are highly potent in antigen uptake and concentrated in 
peripheral lymphoid and nonlymphoid organs (35). In a cocul-
ture system, we first compared the priming capacity of bone mar-
row–derived DCs using OVA-specific CD4+ T cells from OT-II 
(H-2b haplotype) and DO11.10 (H-2d haplotype) mice as respond-
ers. DC stimulators from KO and WT animals, backcrossed onto 
either the C57BL/6 or BALB/c background, exhibited comparable 
stimulatory capacity in this system, as measured by CFSE dilution 
in T cells (Figure 5, B and C). Likewise, priming of OT-I CD8+ 
T cells (H-2b haplotype), which depends on cross-presentation of 
the OVA protein–derived peptide SIINFEKL (36), was similar in 
the presence of KO and WT DCs (Figure 5A).
To explore the priming phase of OVA-specific T cells in vivo, we 
employed adoptive transfer of CFSE-labeled DO11.10 and OT-II 
T cells into Ebag9–/– and Ebag9+/+ recipients (data 
shown for DO11.10). Three days after immu-
nization with OVA, the proliferation rate was 
assessed by CFSE dilution of transgenic CD4+ 
T cells (Figure 6A). In agreement with our in 
vitro data, WT recipients exhibited the same 
priming efficacy as EBAG9-deficient animals. 
Likewise, total numbers of proliferating T cells 
were indistinguishable (data not shown). Finally, 
to test whether antigen-specific Ebag9–/– CTLs 
had a proliferative advantage in vivo, we back-
crossed OT-I TCR-transgenic mice onto the 
Ebag9–/– background and adoptively transferred 
OT-I WT and OT-I KO T cells (CD45.2 congenic 
mouse strain) into congenic hosts (CD45.1 con-
genic mouse strain). Again, following immu-
nization with OVA, a proliferative advantage 
of antigen-specific Ebag9–/– CTLs was not seen 
(Figure 6B). Taken together, it seems unlikely 
that the magnitude of the cytolytic response 
in Ebag9–/– animals in vivo is a consequence of 
altered T cell effector frequencies.
EBAG9 redistributes to the plasma membrane upon 
TCR activation. To address the subcellular local-
ization of EBAG9 in primary CD8+ T cells, OT-I 
TCR transgenic T cells were transduced with 
a retrovirus encoding an EBAG9-GFP fusion 
protein (Figure 7A). The major proportion of 
EBAG9-GFP localized together with the Golgi 
marker GM130 (>86% overlap; Figure 7B) in a 
perinuclear localization. In contrast, quantifica-
tion of colocalization of EBAG9-GFP with the 
endosomal or lysosomal compartment, as deter-
mined by staining of the late endosome/lyso-
some membrane marker Lamp1, the lysosomal 
protease cathepsin D, or the lytic granule marker 
perforin, showed that only a minor proportion 
of vesicular structures overlapped with EBAG9-
GFP localization (Lamp1, 28%; cathepsin D, 
20%; perforin, 13%). We noted that a significant 
pool of EBAG9 molecules redistributed toward 
the plasma membrane after TCR cross-linking 
induced by incubation of T cells on anti-CD3/CD28–coated cov-
erslips (Figure 8A). Under these nonpolarized stimulatory con-
ditions, comparison of EBAG9-GFP with the plasma membrane 
marker CD8a revealed some overlap of both fluorescence signals 
(Pearson’s correlation coefficient, r = 0.55 ± 0.11). In contrast, in 
untreated T cells EBAG9-GFP exhibited a predominantly perinu-
clear staining pattern (r = 0 ± 0).
To investigate the redistribution of EBAG9-GFP upon formation 
of the immunological synapse, we made use of anti-CD3/CD28 
mAb–coated microbeads, which acted as surrogate APCs (Figure 
8B). Granule polarization to the contact site between T cell and 
CD3/CD28-coated microbeads was assessed by anti–cathepsin D 
staining. Whereas in nonpolarized CTLs cathepsin D–positive 
organelles were distributed clearly separate from the perinuclear 
staining pattern of EBAG9-GFP, upon polarization EBAG9-GFP 
was relocated toward the synapse. The EBAG9-GFP–positive organ-
elles surrounded the cathepsin D–containing granules, but a fusion 
between both compartments was rarely seen (r = –0.10 ± 0.18). 
Figure 4
Priming and expansion of antigen-specific CD8+ T cells. (A) Frequency of antigen-specific 
CTLs is unaltered in Ebag9–/– mice. Mice were immunized as described in Figure 3A, and 
splenocytes (on day 4) were cultured in the presence of Tag peptide (1 μg/ml) for another 
4 days. Cells were stained with anti-CD8a mAb and H-2Kb:Ig dimers loaded with Tag 
peptide, followed by flow cytometry analysis. Shown is the percentage of Tag dimer–posi-
tive CD8+ T cells. n = 7 Ebag9+/+ (filled squares) and n = 8 Ebag9–/– mice (open triangles). 
Data are from 2 independent experiments. (B) For intracellular IFN-γ staining, cells were 
stimulated as described in A and stained as described in Methods. The percentage of 
IFN-γ–positive CD8+ cells at day 8 is shown (n = 4 animals per group; data are from 2 inde-
pendent experiments). (C) The proliferative capacity of Ebag9–/– Tag-specific CD8+ T cells 
was unaltered. Mice were immunized as described above, followed by in vitro culture of 
splenocytes (on day 4) in the presence of Tag peptide for another 4 days. For the last 24 
hours, 10 μM BrdU was included in the culture medium. Splenocytes were surface stained 
with H-2Kb dimers and CD8a, followed by intracellular anti-BrdU staining. The percentage 
of proliferating cells was assessed by flow cytometry. (D) As described in C, the prolifera-
tive rate (percentage) of CD8+IFN-γ+ effector T cells was assessed by intracellular BrdU 
staining. Horizontal bars indicate the mean value.
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Taken together, since many organelles including early endosomes 
cluster in the perinuclear region adjacent to the Golgi complex, the 
calculated colocalization with GM130 might indicate an associa-
tion with several organelles in close proximity. However, the data 
exclude the localization of EBAG9-GFP to preformed secretory 
lysosomes in resting T cells. This is in agreement with our previous 
experiments in epithelial and neuronal cell lines, in which we used 
confocal microscopy and electron microscopy (12, 37).
EBAG9 interacts with the adaptor protein γ2-adaptin. To gain mechanis-
tic insight into the cellular function of EBAG9, we scored for novel 
interaction partners employing the yeast 2-hybrid system. Screen-
ing of a human lymph node library yielded 3 interacting clones, 
BLOC-1, subunit 2 (BLOS2), Snapin, and γ2-adaptin (Table 1). 
BLOS2 and Snapin were shown to be subunits of the BLOC-1 
complex, a multisubunit protein complex essential for endosomal-
lysosomal sorting and lysosome-related organelle formation (17). 
In coimmunoprecipitation experiments from cell lines (data not 
shown), we failed to verify a physical interaction among EBAG9, 
BLOS2, and Snapin (data not shown).
To assess whether EBAG9 and the novel interaction partner 
γ2-adaptin also associate in eukaryotic cells, we performed pull-
down experiments with ear domain of γ2-adaptin (γ2-ear) GST 
fusion protein studies (Figure 9, A and B). A selective interac-
tion between EBAG9-GFP and the ear domain of γ2-adaptin was 
Figure 5
Similar efficiency of EBAG9-deficient and WT DCs for priming of OVA-specific T cells in vitro. (A) DCs derived from Ebag9+/+ and Ebag9–/– mice 
(H-2b haplotype) were pulsed overnight with 100 μg/ml OVA protein. CFSE-labeled naive OT-I T cells (1 × 105) were stimulated with pulsed or 
unpulsed DCs (1 × 104) for 3 days. Cells were analyzed by flow cytometry, and T cells were gated for the expression of the clonotypic TCR or 
CD8a and CFSE. Shown is a representative FACS plot of gated CD8+ cells. Proliferation of T cells was evaluated according to CFSE dilution. 
Numbers indicate the percentage of proliferated CD8+ T cells within the gate. Representative data from 2 independent experiments with DCs 
from at least 6 animals per group. No significant differences were seen. (B) DCs (H-2d haplotype) were generated and pulsed with OVA protein 
(75 μg/ml) as described in A, followed by a 3-day coculture with CFSE-labeled OT-II CD4+ T cells. T cells were gated as described in A. Numbers 
indicate the percentage of proliferated CD3+ T cells within the gate. Shown are representative data from 3 independent experiments. DCs were 
taken from at least 6 animals per group. (C) DCs (H-2d haplotype) were pulsed for 2 hours with OVA-derived peptide (5 μg/ml), followed by a 
coculture with DO11.10 CD4+ T cells. T cells were gated as described in A. Shown are representative data from 4 independent experiments. DCs 
were taken from at least 9 animals per group. Percentages indicate the percentage of proliferated CD3+ T cells within the gate.
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observed in binding assays using recombinant fusion proteins. In 
contrast, the ear domain of γ1-adaptin failed to bind EBAG9-GFP 
(Figure 9A). The association was further confirmed by coimmuno-
precipitation of endogenous γ2-adaptin (but not γ1-adaptin) and 
EBAG9 in stably transfected MDA-MB435-EBAG9-GFP cells (Fig-
ure 10B). Next, using truncated GFP-fusion proteins of EBAG9, 
the relevant domain for binding to the γ2-adaptin ear domain was 
mapped to aa 30–175, a region of the EBAG9 protein linking the 
membrane proximal domain (aa 8–27) and the predicted coiled-
coil domain (aa 176–206) (Figure 9B and Figure 10A). In confo-
cal microscopy analysis, we examined the subcellular localization 
of EBAG9-GFP and γ2-adaptin in Jurkat T cells. Consistent with 
the pulldown and coimmunoprecipitation experiments, we found 
significant overlap between EBAG9-GFP and γ2-adaptin in peri-
nuclear structures (mean r = 0.469; Figure 9C). Collectively, these 
data indicate that EBAG9 interacted physically with γ2-adaptin.
EBAG9 deficiency affects the endosomal-lysosomal trafficking pathway. 
The association of EBAG9 with the adaptor molecule γ2-adaptin 
might indicate a modulatory function of EBAG9 on the trafficking 
route toward the endosomal or lysosomal compartment. To assess 
the consequences of EBAG9 deletion on this 
section of the secretory pathway, immunoblot 
analysis of Ebag9+/+ and Ebag9–/– CD8+ total cell 
lysates was performed. Comparable expres-
sion levels were observed of several SNARE 
and SNARE-associated molecules (SNAP23; 
VAMP7; Snapin; syntaxin 4, 7, 8, and 13; synap-
totagmin VII), which are involved in lytic gran-
ule release at the plasma membrane or localized 
to the endosomal-lysosomal pathway (Figure 
11A). Thus, EBAG9 deletion did not result in 
any apparent compensatory changes in the 
expression of those proteins.
To examine whether endogenous SNARE 
molecules were associated with distinct mem-
brane compartments in Ebag9+/+ and Ebag9–/– 
CD8+ T cells, a microsomal membrane fraction 
was further separated by Optiprep gradient 
centrifugation and analyzed in conjunction 
with immunoblotting. Whereas we found no 
significant difference in the distribution of the 
plasma membrane SNARE molecules syntaxin 4 
or SNAP23 (data not shown) or in the distribu-
tion of the recycling endosome marker syntaxin 
13, the late endosome marker syntaxin 7 was 
present in lighter membrane fractions in KO 
CD8+ T lymphocytes compared with WT T cells 
(Figure 11, B and C). To validate the resolution 
capacity of the Optiprep gradient, enzymatic 
activity of the conventional lysosome marker 
β-hexosaminidase and the Golgi complex marker 
GM130 was determined. Peak activity for the 
lysosomal marker was seen in fractions 6–8, and 
GM130 exhibited major peaks in fractions 3–5 
in both genotypes (Supplemental Figure 5).
To study the potential role of EBAG9 in the 
process of granule biogenesis and maturation, 
we examined the morphology of the lytic gran-
ule compartment by electron microscopy. CTLs 
were labeled overnight (for 18 hours) with the 
endocytic tracer horseradish peroxidase to load lytic granules. 
Mature lytic granules, characterized by their typical electron-dense 
cores, were analyzed and measured by randomly selecting 90 cells 
from independent sections and mice (n = 4 per group) (Figure 
12A). Relative size distribution revealed a statistically significant 
shift toward smaller granule diameters in EBAG9-deficient CTLs 
(Figure 11B; P < 0.005, ANOVA). The diameters of lytic granules 
decreased on average from 1,637 nm (± 35.7 SEM) in WT CTLs to 
1,461 nm (± 31.2 SEM) in Ebag9–/– CTLs, corresponding to a 30% 
volume decrease (P < 0.001, Student’s t test). These results indi-
cate that EBAG9 modulated the ultimate generation of secretory 
granules in CTLs.
Formation of the immunological synapse remains unaffected in Ebag9–/– 
CTLs. To investigate the formation of the immunological synapse, 
we made use of anti-CD3 mAb–coated microbeads. We analyzed the 
polarization of the lytic granule marker perforin to the site of con-
tact between T cell and microbeads by confocal microscopy analy-
sis (Figure 13, A and B). In this assay, granule polarization to the 
contact site between T cell and CD3-coated microbeads was first 
assessed in differential interference contrast images, which allowed 
Figure 6
Loss of EBAG9 does not affect the proliferation of naive, OVA-specific transgenic T cells in 
vivo. (A) CFSE-labeled naive CD4+ DO11.10 T cells (1 × 106) were adoptively transferred 
into Ebag9–/– and Ebag9+/+ recipients (Balb/c, H-2d haplotype). Eighteen hours later, mice 
were immunized by s.c. injection of 100 μg OVA protein and 25 μg CpGs. Control WT and 
KO animals received T cells but no OVA protein (naive). Proliferation of transferred T cells 
in draining lymph nodes was analyzed by flow cytometry at day 3. Representative FACS 
plots of gated CD4+ cells from pooled draining lymph nodes (WT, n = 4; KO, n = 5 mice). 
Numbers indicate the percentage of proliferated CFSE-labeled KJ1.26+ responder T cells 
in WT or KO recipients within the gate. No differential stimulation of responder T cells was 
observed in WT or KO recipients. (B) Naive OT-I/Ebag9–/– (n = 4 mice) and OT-I/Ebag9+/+ 
CD8+ (n = 4 mice) T cells (CD45.2 congenic mouse strain) were CFSE labeled and trans-
ferred i.v. into congenic (CD45.1 congenic mouse strain) recipients (5 × 105 cells). Twenty 
hours later, animals were immunized i.v. with OVA protein (1 μg/g body weight) and CpGs 
(25 μg). Control groups included a non-immunized animal. Two days later, proliferation 
of transferred T cells in spleen was analyzed by flow cytometry. Transferred T cells were 
detected by anti-CD45.2 (LY-5.2) staining. Numbers indicate the percentage of proliferated 
CFSE-labeled CD45.2+ responder T cells in WT or KO recipients within the gate. Shown 
are representative data for 5 congenic recipients of OT-I/Ebag9–/– T cells and 4 congenic 
recipients of OT-I/Ebag9+/+ T cells.
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the identification of T cell–bead conjugates showing clear cell-bead 
contact. Whereas at the 0-minute time point we observed almost 
no focused localization of perforin with beads at the contact site, 
there was clear localization after 10 minutes, and localization was 
even more focused at the 30-minute time point. In EBAG9-defi-
cient CTLs, the lytic granules polarized toward the immunological 
synapse at the same rate as the granules from WT CTLs.
To obtain further proof for the mobilization of cytolytic gran-
ules to the immunological synapse, anti–cathepsin D staining 
was used as an alternative marker (38). Furthermore, to address 
potential kinetic differences in conjugate formation, association 
between T cells and CD3/CD28-coated microbeads was allowed 
to form for only 15 minutes, followed by the analysis of conju-
gate formation and granule reorientation. Whereas unconjugated 
CD8+ cells displayed discrete, punctate staining of intracellular 
vesicles containing cathepsin D in a nonpolarized pattern, effec-
tor T cells conjugated to beads polarized cathepsin D toward 
the T cell–bead interface in a clearly distinguishable pattern 
(Supplemental Figure 6). Among the conjugates analyzed (n = 30 
for each genotype), comparable numbers of conjugates showed 
a tight polarization of lytic granules toward the immunologi-
cal synapse. In addition, simultaneous detection of lytic granule 
reorientation and localization of the signaling zone molecule Lck 
was performed in a separate experiment. CTLs were allowed to 
form conjugates for 15 minutes, followed by anti–granzyme B 
and anti-Lck staining. Synapse formation for bead-conjugated 
T cells was assessed by the reorientation of both markers. Clusters 
of coalesced granzyme B–stained lytic granules could be identi-
fied exclusively in conjugated T cells, surrounded by Lck staining 
(Supplemental Figure 7B). This pattern differed markedly from 
unconjugated, nonpolarized T cells in which granules were scat-
tered at the cell periphery (Supplemental Figure 7A). Consistent 
Figure 7
Subcellular localization of EBAG9 in primary T cells. (A) Splenocytes from OT-1–transgenic C57BL/6 mice were stimulated and transduced 
with retrovirus encoding EBAG9-GFP as described in Methods. Cells were fixed, permeabilized, and stained with antibodies directed against 
GM130, cathepsin D, Lamp1, or perforin and were analyzed by confocal microscopy. Arrows indicate regions of interest. Insets show zoomed 
magnifications of 2- to 3-fold. Scale bars: 10 μm. (B) Quantitative analysis of EBAG9-GFP structures overlapping with the indicated organ-
elle-specific marker. Colocalization was defined as r > 0.5. The percentage overlapping markers is the percentage of organelles that had 
r > 0.5. n > 28 cells for each marker analyzed in at least 2 independent experiments (for EBAG9-GFP and anti-GFP, rmax = 0.81; for anti-
GM130 and -CD8a, rmin = 0).
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with the shorter length of conjugate formation (15 minutes), con-
jugated T cells in rare cases contained single, nonpolarized lytic 
granules. Among the conjugates analyzed (n = 10 for each group), 
similar numbers of granules showed a tight polarization of the 
majority of granules at the synapse. We conclude that EBAG9 is 
not involved in the secretion process at the plasma membrane 
itself, but rather acts upstream through regulation of trafficking 
steps and maturation of secretory lysosomes.
Altered distribution of a lysosomal membrane marker and lysosomal 
hydrolases in Ebag9+/+ and Ebag9–/– CTLs. Next, we wanted to deter-
mine whether loss of EBAG9 influenced the supply of secretory 
lysosomes with cytolytic effector molecules. We examined the 
distribution of the late endosome/secretory lysosome mem-
brane marker Lamp1 and the intraluminal hydrolase granzyme B 
in CD8+ T cells of Ebag9+/+ and Ebag9–/– mice by quantitative con-
focal microscopy analysis. Colocalization of granzyme B and 
Lamp1 with the Golgi complex marker GM130 or lysosomal 
marker cathepsin D was quantified by randomly selecting dots of 
granzyme B or Lamp1 immunofluorescence. Subsequently, the 
overlap with cathepsin D or GM130 was quantified by calculat-
Figure 8
Activation-dependent intracellular 
redistribution of EBAG9 in CTLs. 
(A) EBAG9 redistributes toward the 
plasma membrane upon T cell activa-
tion. For non-polarized activation via 
the TCR, EBAG9-GFP–transduced 
T cells were cultured on plate-bound 
anti-CD3ε and anti-CD28 mAbs 
(+CD3) or left untreated (–CD3). 
Cells were fixed and stained with an 
anti-CD8a antibody without permea-
bilization. Colocalization between 
EBAG9 and CD8a was quantified by 
calculating the Pearson’s correlation 
coefficient. At least 10 cells were ana-
lyzed in 2 independent experiments. 
Scale bar: 10 μm. (B) EBAG9 moves 
to the immunological synapse upon 
polarized stimulation of CTLs. CTLs 
were generated and transfected with 
EBAG9-GFP as described in Meth-
ods. CTLs were mixed with CD3/
CD28-precoated Dynabeads, incu-
bated for 5 minutes at 37°C, plated on 
coverslips, and incubated for another 
30 minutes before fixation and per-
meabilization. Lytic granules were 
stained with anti–cathepsin D anti-
body (red). Representative images 
of non-conjugated and non-polarized 
T cells are shown in the top row. Polar-
ized T cells with conjugated beads 
are shown in bottom 3 rows. Data are 
from 1 experiment with CTLs from 3 
animals. At least 20 conjugates were 
analyzed (r = –0.10 ± 0.18). Scale 
bars: 5 μm. Insets have additional 
magnifications of 2- to 3-fold.
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ing the Pearson’s correlation coefficient for each dot. As shown 
in the histogram of Figure 14A, the Pearson’s correlation coeffi-
cient distribution between granzyme B and cathepsin D shifted to 
larger r values in Ebag9–/– CTLs, reflecting a more efficient sorting 
of granzyme B to the lysosomal compartment in Ebag9–/– CTLs 
(mean r = 0.182) compared with Ebag9+/+ CTLs (mean r = 0.059; 
P < 0.0001). Similar results were obtained for the grade of colo-
calization between perforin and cathepsin D (data not shown), 
suggesting that perforin as well as granzyme B undergo a more 
efficient targeting to secretory lysosomes in Ebag9–/– CTLs.
In contrast, the grade of colocalization between Lamp1 and 
cathepsin D decreased in Ebag9–/– T cells (Figure 14B; Ebag9+/+, 
mean r = 0.352; Ebag9–/–, mean r = 0.176; P < 0.0001), indicating 
a perturbed targeting of Lamp1 to lysosomes in Ebag9–/– CD8+ 
T cells. Of course, with each lytic granule marker there were also 
single cells with a high level of colocalization. We measured overlap 
between granzyme B and GM130 as a control and found almost 
no overlap, which was comparable in Ebag9+/+ (mean r = –0.026) 
and Ebag9–/– (mean r = –0.017; P > 0.7) CTLs (Supplemental Figure 
8A). Similar results were obtained for the grade of colocalization 
between Lamp1 and GM130 (Ebag9+/+, mean r = 0.074; Ebag9–/–, 
mean r = 0.082; P > 0.5; Supplemental Figure 8B).
Deletion of EBAG9 enhances sorting of the lysosomal hydrolase cathep-
sin D. To examine the involvement of EBAG9 in the dynamics of 
protein transport, we determined the intracellular transport rate 
of newly synthesized proteins. CTLs from WT and EBAG9-defi-
cient mice were pulse-labeled for 5 minutes with [35S] methio-
nine/cysteine, washed, and transferred to chase medium (39). 
Cells were further incubated on uncoated or CD3/CD28-pre-
coated plates to distinguish constitutive and inducible release. At 
the time points indicated in Supplemental Figure 9, the amount 
of labeled protein was determined in the medium. Constitutive 
discharge of radiolabeled protein was indistinguishable between 
WT and KO CTLs (data not shown). However, starting 90 min-
utes after transfer onto CD3/CD28-coated plates, the increase 
of regulated release was significantly higher in EBAG9-deficient 
CTLs (Supplemental Figure 9; P ≤ 0.05, Mann-Whitney test). 
These data suggested that the intracellular transit time of secre-
tory proteins, as modified specifically through TCR activation, 
is changed in EBAG9-deficient T cells.
To obtain a more specific kinetic description of endosomal-
lysosomal protein sorting, we used pulse-chase labeling in com-
bination with subcellular fractionation and cathepsin D–specific 
immunoprecipitation. Cathepsin D, which is commonly appreci-
ated as a secretory lysosome marker, is synthesized as a 53-kDa 
precursor form and is proteolytically converted within the endo-
somal-lysosomal compartment via a 47-kDa intermediate into the 
mature lysosomal form (31 kDa) (40, 41). A postnuclear superna-
tant from CTLs was separated in a 2-step procedure to enrich the 
lysosomal compartment. Distribution of radioactivity changed 
with time, but corresponding Ebag9+/+ and Ebag9–/– samples 
(taken after 0 and 100 minutes of chase) exhibited comparable 
amounts of counts over the gradient (Figure 15C). At the 100-
minute chase point, we recovered significantly higher amounts of 
the lysosomal form of cathepsin D (31 kDa) in fractions 6 and 7 
from EBAG9-deficient mice (Figure 15B). Based on densitometric 
scanning, we calculated the ratios of precursor/intermediate/lyso-
somal form in fraction 7 at 100 minutes of chase to be 0.9:1:1.1 
for Ebag9+/+ and 0.9:1:2.2 for Ebag9–/–. At 0 minutes of chase, we 
obtained only minor amounts of cathepsin D from this region, 
but no lysosomal form (Figure 15A). By immunoblot analysis, 
total amounts and the distribution of granzyme B were not dis-
cernible, and peak fractions 6 and 7 overlapped with the recovery 
of lysosomal cathepsin D from these fractions. Thus we infer that 
loss of EBAG9 causes enhanced sorting of the precursor form of 
cathepsin D to secretory lysosomes.
Discussion
The results presented here identify EBAG9 as an important player 
in the control of secretory lysosome release in CTLs. We not only 
present what we believe is a novel molecular component of the 
regulated secretory pathway within the immune system, but also 
provide evidence for a systemic immunosurveillance function of 
EBAG9 through genetic deletion in mice.
Apart from the genetic analysis of rare human disease-causing 
mutations and their corresponding murine mutant strains (3, 4), 
little is known about the proteins that mediate protein sorting into 
and fusion of lytic granules with the plasma membrane in CTL. 
In Ebag9–/– mice, we obtained an enhanced release of granzyme A 
when CTLs were triggered with anti-CD3 antibodies. This observa-
tion is consistent with the effect of EBAG9 upon overexpression in 
PC12 cells, since loss of EBAG9 might lower an inhibitory step in 
Ca2+-dependent regulated exocytosis (12). In contrast, the capac-
ity of EBAG9 to regulate specifically the granzyme A pathway, but 
not CTLA4 targeting, is in agreement with results from Ashen 
mice, which have a loss of function in the Rab27a gene (42). The 
enhanced in vitro release of granzyme A translates into a substan-
tially increased capacity of Ebag9–/– CTLs to kill allogeneic target 
cells. Since the frequency of allogeneic CTLs might confound the 
interpretation of this result, we additionally conducted an anti-
gen-specific in vivo kill assay (32). CTL cytolytic capacity against 
syngeneic splenocytes that carry the dominant Tag peptide IV was 
assessed in primary and memory responses. In agreement with our 
in vitro results, Ebag9–/– mice killed their targets more efficiently 
than did Ebag9+/+ animals.
Since effector cell frequencies could affect the interpretation of 
the cytotoxicity assays (43, 44), we determined numbers of antigen-
Table 1
Yeast 2-hybrid screening
Bait (BD-) Prey (AD-) Interaction
Lamin C SV40 T-antigen –
p53 SV40 Tag +++
EBAG9 Empty vector –
EBAG9 SV40 Tag –
EBAG9 BLOS2 +++
Empty vector BLOS2 –
EBAG9 Snapin +++
Empty vector Snapin –
EBAG9 γ2-Adaptin +++
Empty vector γ2-Adaptin –
Yeast 2-hybrid screening of a lymph node cDNA library revealed 3 
EBAG9-interacting proteins: BLOS2, Snapin, and γ2-adaptin. The indi-
cated GAL4-BD and GAL4-AD plasmids were cotransformed in yeast 
cells. The unrelated molecules BD–Lamin C and AD–SV40 Tag repre-
sented negative controls; the combination BD-p53 and AD–SV40 Tag 
provided the positive controls. –, no interaction; +++, strong interaction, 
as determined by growth in the absence of histidine and adenine and by 
α-galactosidase (Mel1) activity.
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specific CTLs during the priming and effector phases using Kb:Tag 
peptide dimer staining. Furthermore, we addressed the priming 
capacity of KO and WT DCs in vitro and in vivo, but a difference 
between the genotypes was not seen. In conjunction with the com-
parable proliferation rate of EBAG9-deficient OT-I cells, we suggest 
that the magnitude of the cytolytic activity in EBAG9-deficient ani-
mals is due to an increased secretion of lytic granule content.
A contribution of NK cells to the elimination of peptide-pulsed 
splenocytes could be excluded, thus we infer that EBAG9 activity 
may define a discrete secretory mechanism in CTL, which is not 
found in NK cells. Furthermore, this finding indicates that the pre-
cise composition of the exocytosis machinery might vary between 
hematologic cell types (2). While NK cells can provide secretory 
granules upon activation or inhibition of cell surface receptors 
almost immediately, CTLs require a longer priming and matura-
tion process prior to gaining cytolytic competence (45, 46). Strik-
ing differences between CTLs and NK cells include cell surface and 
lysosomal proteins involved in antigen presentation, capturing, and 
internalization, which enable NK cells to act as APCs to CD4+ T cells 
(47). Furthermore, differences between primary NK cells and NK 
cell lines with regard to protein profiles in secretory lysosomes were 
observed (48). Thus, it could be envisaged that CTLs and NK cells 
employ individual vesicular transport pathways to supply secretory 
lysosomes with cytolytic effector molecules. To our knowledge, a 
comparative proteomic approach addressing the composition of 
secretory lysosomes from primary NK cells and defined matura-
tional stages of CTLs has not been demonstrated yet.
The immunological phenotype of EBAG9-deleted mice could be 
explained mechanistically through the identification of γ2-adaptin 
as an interaction partner of EBAG9. Despite the structural similar-
ities to the γ1 subunit of the AP1 complex, which itself functions 
as an adaptor complex for transport carriers between the TGN and 
endosome, a unique function of γ2-adaptin was identified. To our 
knowledge, γ2-adaptin–containing AP complexes have not been 
Figure 9
EBAG9 interacts with γ2-adaptin in vitro. (A) Jurkat cells (2 × 106) were transiently transfected with EBAG9-GFP and solubilized in Triton 
X-100–containing lysis buffer. Cell lysate was incubated with the indicated immobilized GST-fusion protein, and bound EBAG9-GFP was ana-
lyzed by SDS-PAGE, followed by immunoblotting with biotinylated anti-GFP antibody. An aliquot (1/6 volume of the reaction mixture) of the cell 
lysates was immunoblotted for expression of EBAG9-GFP (input). (B) The membrane proximal attachment domain (MA) alone (aa 8–27) and the 
coiled-coil domain (CC; aa 176–206) were dispensable for the interaction of EBAG9-GFP with the ear domain of γ2-adaptin. MDA-MB435 cells 
(2 × 106) transfected with EBAG9-GFP (WT) or deletion mutants (MA, ΔCC, ΔMA, ΔMAΔCC) were lysed in Triton X-100–containing lysis buffer, 
and GST pulldowns were performed as described in A. Input was 1/6 volume of the reaction mixture. To control for an equal loading of GST 
proteins, membranes were stained with Ponceau (input GST). At right is a schematic representation of EBAG9-GFP and its deletion mutants.
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identified so far. In addition, localization to the cytoplasm and 
perinuclear structures of the cis-Golgi apparatus as well as localiza-
tion to CD63+ granules, late endosomes, and multivesicular bod-
ies (MVBs) differed markedly from the localization described for 
AP1 (7, 8). Evidence for a sorting function within the endosomal- 
lysosomal sorting pathway came from virus infection models. For 
HBV maturation it was shown that γ2-adaptin interacted via its 
ear domain with the viral L-protein, whereas the head domain 
recruited the core particle (11, 49). Thus, γ2-adaptin may orga-
nize HBV assembly platforms on endosomal membranes. Func-
tionally, depletion of γ2-adaptin correlated with diminished HBV 
virion release without compromising constitutive protein secre-
tion. Unexpectedly, it was also shown that γ2 overexpression had 
the same effect on HBV and retroviral Gag protein release, which 
was partially explained by impos-
ing a dominant inhibitory effect on 
endogenous γ2-adaptin (50). The 
unique function of γ2-adaptin may 
rely on its ubiquitin-binding activ-
ity, a common feature of monomeric 
adaptors (e.g., epsin and hepatocyte 
growth factor–regulated tyrosine 
kinase substrate), which control 
ubiquitin-dependent endocytotic 
sorting processes to the MVB/lyso-
some. Although differences between 
cellular physiology and virus infec-
tions could be a concern, from the 
HBV model it was inferred that 
γ2-adaptin may not act as a typical 
vesicle-forming adaptor, but func-
tions in connecting HBV production 
and in the subsequent selection of 
cargo protein destined for inclusion 
into coated vesicles (11).
In support of a role in the endosom-
al/MVB sorting pathway, it was shown 
that γ2-adaptin depletion impaired 
the degradation of internalized epi-
dermal growth factor and resulted in 
defective MVB morphology in liver 
and HeLa cells (51). More specifically, 
γ2-adaptin depletion induced an 
endosomal enlargement. Conversely, 
in EBAG9-deleted CTLs we obtained 
reduced secretory lysosome volumes, 
indicating that EBAG9 could act as a 
negative modulator on the endosom-
al transport route. In this scenario, 
EBAG9 inhibits γ2-adaptin cargo 
recruitment and sorting functions. 
As a potential consequence of this 
association, EBAG9 could restrain 
the upregulated sorting to the secre-
tory lysosome compartment in CTLs. 
The absence of EBAG9 would allow 
enhanced activity of γ2-adaptin in 
these processes instead.
An interaction between EBAG9 
and γ2-adaptin, as revealed by yeast 
2-hybrid screening, was confirmed by GST–γ2-adaptin pulldown 
and coimmunoprecipitation studies. In the pulldown assay, the 
ear domain was sufficient to recruit EBAG9-GFP, which is con-
sistent with the role of this domain to bind other accessory mol-
ecules (rabaptin-5, γ-synergin, enthoprotin, and NECAP1) (52). 
Using truncated versions of EBAG9, we identified a sequence 
between aa 30 and aa 175 as an interaction domain sufficient for 
γ2-ear domain binding. This sequence was predicted to be largely 
unstructured and therefore accessible for interactions with γ2-ear 
domains. In support of a physical interaction, strong colocal-
ization between EBAG9-GFP and γ2-adaptin–HA was seen in a 
perinuclear region of T cells. This result is in agreement with the 
colocalization of EBAG9 and the cis-Golgi marker GM130 under 
resting conditions (12, 37) and with the reported colocalization 
Figure 10
Coimmunoprecipitation of EBAG9 and γ2-adaptin in vivo. (A) GFP or EBAG9-GFP stably expressing 
MDA cells were transiently transfected with γ2-adaptin–HA. Cells were solubilized in Triton X-100 lysis 
buffer and subjected to immunoprecipitation with anti-GFP mAb. Coimmunoprecipitated γ2-adaptin–
HA was detected by immunoblotting with an anti-HA mAb. EBAG9-GFP and GFP were detected with 
biotinylated anti-GFP antibody (input GFP). Input was 1/100 volume of the reaction mixture. Lane 1, 
MDA-MB435-EBAG9-GFP; lane 2, MDA-MB435-GFP plus γ2-adaptin–HA; lane 3, MDA-MB435-
EBAG9-GFP plus γ2-adaptin–HA. (B) Stably transfected MDA-MB435-EBAG9-GFP and GFP-trans-
fected control cells (1 × 107) were solubilized in Triton X-100–containing lysis buffer and subjected to 
immunoprecipitation with anti-GFP mAb. Coimmunoprecipitated endogenous γ2-adaptin was detected 
in immunoblotting with a γ2-adaptin–specific antibody. EBAG9-GFP and GFP were detected with 
biotinylated anti-GFP antibody (input GFP). (C) Colocalization of EBAG9-GFP and γ2-adaptin in a 
perinuclear localization. Jurkat cells were cotransfected with EBAG9-GFP and γ2-adaptin–HA. Cells 
were fixed, permeabilized, and then stained with anti-HA mAb. Images were analyzed by confocal 
microscopy, and colocalization was assessed by calculating the Pearson’s correlation coefficient r of 
at least 30 cells analyzed in 2 independent experiments (mean r = 0.469). For EBAG9-GFP and anti-
GM130, mean r = 0.63 (for EBAG9-GFP and anti-GFP, rmax = 0.95). Scale bar: 5 μm.
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of γ2-adaptin in epithelial cell lines with the cis-Golgi/intermedi-
ate compartment marker Helix pomatia lectin (8). Since it was also 
shown that γ2-adaptin resides together with the HBV L-protein at 
the Golgi complex, collectively these data support the notion that 
EBAG9 and γ2-adaptin interact physically and functionally.
An alternative interpretation of the functional role of EBAG9 in 
endosomal-lysosomal sorting and lysosome-related organelle for-
mation involves an interaction with the BLOC-1 subunits BLOS2 
and Snapin, both of which were retrieved in the yeast 2-hybrid 
assay. BLOC-1 regulates specific cargo-trafficking steps through 
interactions with other known trafficking regulators, including 
AP3 and BLOC-2 (53, 54). Within the secretory pathway, BLOC-1 
is required for cargo-specific sorting from early endosomes toward 
lysosome-related organelles (55). However, a functional associa-
tion between EBAG9 and the BLOC-1 complex is difficult to rec-
oncile with our data. BLOC-1 defects, as shown in pallidin, muted, 
and sandy mouse strains, had no functional consequences on CTL 
cytolytic activity (55). Thus, it seems unlikely that CTL granules 
mature in the absence of those subunits while still dependent on 
Snapin and BLOS2. Furthermore, we failed to validate the interac-
tion with Snapin and BLOS2 in coimmunoprecipitation experi-
ments; in particular, we did not obtain evidence for the retrieval of 
those molecules within the context of an intact BLOC-1 complex.
EBAG9 localization within cytotoxic T cells is dynamic, as shown 
by the TCR-induced relocalization toward the immunological 
synapse. A similar activation-dependent redistribution toward 
the plasma membrane and the immunological synapse has been 
shown recently for the Wiskott-Aldrich syndrome protein-interact-
ing protein (56), which turned out to be essential for lytic granule 
release in NK cells. We have previously shown that EBAG9, upon 
nerve growth factor–induced differentiation in neuroendocrine 
cells, redistributed toward secretory vesicles in the vicinity of the 
plasma membrane. Since EBAG9 exhibits a palmitoylation anchor 
and is subject to phosphorylation, we suggest that these modifica-
tions contribute to EBAG9 relocalization in T cells as well (12). 
The relocalization would also be consistent with the colocalization 
between EBAG9 and GM130 and the known polarization of the 
microtubule-organizing center and associated organelles toward 
the signaling platform at the T cell–target cell contact site. Under 
activated conditions, such trafficking would position EBAG9-
containing structures in proximity to the endosomal-lysosomal 
compartment. More recently, it could be shown that lytic granule 
maturation is a stepwise process that involves the hMunc13-4– 
dependent fusion of Rab11-containing recycling endosomes with 
Rab27a+ late endosomal vesicles (57). This step is followed by a 
separate redistribution of these endosomal exocytic vesicles and 
Figure 11
Redistribution of the endosomal vesicle marker syntaxin 7. (A) Identical expression levels of SNARE and SNARE-associated proteins in WT 
and EBAG9-deficient CTLs. Equal amounts of CD8+ T cell extracts were analyzed by SDS-PAGE, followed by immunoblotting with the indicated 
antibodies. Synaptotagmin VII occurred in several splice variants. One representative experiment of 9 animals analyzed (per group) is shown. 
(B) A postnuclear supernatant from 8 × 107 to 1 × 108 Ebag9+/+ or Ebag9–/– CTLs (day 6–7) was centrifuged at 100,000 g for 45 minutes to obtain 
a microsomal fraction. Microsomes were further resolved on a continuous OptiPrep gradient. Fractions (0.75 ml) were collected from the top of 
each gradient, and proteins were precipitated with TCA. Samples were resolved by SDS-PAGE and analyzed by immunoblot using polyclonal 
antibodies as indicated. Data are representative of 3 experiments performed, with pooled CTLs from 9 mice per group. (C) Protein marker distri-
bution was quantified by densitometric scanning and expressed as percentage of the total amount present in the microsomal pellet.
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lysosomal cytotoxic granules toward the immunological syn-
apse. Colocalization between cytotoxic granules, containing per-
forin, and the assembled Rab11+/Rab27a+ endosomal structures 
occurred only when the granules were polarized, suggesting that a 
late step of granule maturation may proceed immediately prior to 
secretion. Notably, the efficiency of the latter process was strongly 
dependent on the expression levels of hMunc13-4, with a moderate 
efficiency in the presence of endogenous hMunc13-4 and a strong 
correlation when hMunc13-4 was overexpressed. Since EBAG9 in 
WT CTLs equipped with endogenous hMunc13-4 was found to 
reside mainly in a synapse compartment separate from polarized 
cytotoxic granules, these data suggest that the molecule could 
restrain sorting to the lytic granules from an upstream position.
Polarization of lytic granules toward the immunological synapse 
was unaltered in Ebag9–/– mice, and hence vesicle docking and teth-
ering were apparently not influenced. Instead, in support of a piv-
otal function of EBAG9 in endosomal-lysosomal protein sorting, 
we found that loss of EBAG9 imposed a change in the steady-state 
distribution of the target SNARE syntaxin 7, which is required for 
both homotypic late endosome fusion and heterotypic fusion with 
lysosomes (58, 59). In contrast to syntaxin 7, in our subcellular 
fractionation experiments we observed no relocalization of the 
plasma membrane SNARE syntaxin 4 or the recycling endosome 
marker syntaxin 13.
Confocal microscopy analysis revealed a distinct colocalization 
pattern of lysosomal marker molecules Lamp1, granzyme B, and 
cathepsin D in EBAG9-deleted and WT CTLs. This suggested that 
granzyme B is prone to a more efficient trafficking to lysosomes 
in EBAG9-deficient CTLs. An important distinction between these 
markers includes their sorting pathways (6, 60). As an integral lyso-
somal membrane protein, Lamp1 does not require sorting recep-
tors, since its cytosolic tail interacts directly with multimeric AP 
proteins, foremost AP3 for lysosomal targeting. In contrast, the 
acid hydrolases cathepsin D and granzyme B associate with the 
M6PR for proper delivery from the TGN to endosomes. Of course, 
the finding of a decreased targeting of Lamp1 to cathepsin D–con-
taining lysosomes in EBAG9-deficient CTLs could be equally inter-
preted as a decreased targeting of cathepsin D to Lamp1-containing 
lysosomes. We consider this view to be unlikely, since loss of EBAG9 
causes enhanced sorting of the soluble precursor form of cathep-
sin D to the lysosomal compartment, as shown by pulse-chase and 
subcellular fractionation analysis. A role for EBAG9 in the proper 
delivery of secretory lysosome content and lytic granule maturation 
is further substantiated by an altered vesicle size distribution with 
smaller granule volumes in EBAG9-deficient CTLs. In agreement 
with the involvement of EBAG9 in the regulated secretory pathway 
in CTLs, transit dynamics of secretory proteins upon TCR engage-
ment was found to be enhanced. Taken together, we conclude that 
EBAG9 tightly cooperates with γ2-adaptin in the sorting of cyto-
lytic effector molecules to secretory lysosomes. Immunologically, 
this modulation of endosomal-lysosomal trafficking is intimately 
linked with the cytolytic capacity of activated CTLs.
Finally, estrogen induces gene activation of EBAG9 (22–24). 
Since estrogen receptor expression on CD4+ and CD8+ T cells 
has been recorded, EBAG9 would be in a position to modulate 
the cytolytic T cell responsiveness toward antigenic target cells, 
depending on the prevalent estrogen levels (61). In view of the 
suggested immunosurveillance function of CTLs in cancer, the 
potential therapeutic benefit of estrogen activity inhibition war-
rants further study.
Methods
Generation of EBAG9-deficient mice. Genomic Ebag9 DNA isolated from a 
129/SV BAC genomic library was introduced into the pTV0 vector (62), 
and exons 2 to 4 were replaced by a neomycin cassette. Linearized vector 
was electroporated into E14-1 ES cells. Homologous recombination in ES 
cells was selected for using G418 and gancyclovir treatment and was veri-
fied by Southern blot hybridization. Two independent ES cell clones were 
expanded and used for microinjection into C57BL/6 blastocysts. Germ-
line-mutated mice were bred to C57BL/6 and BALB/c backgrounds and 
Figure 12
Altered size distribution of secretory lysosomes in EBAG9-deficient CTLs. (A) CTLs (day 6–7) obtained from MLR were labeled overnight with 
horseradish peroxidase to load the lytic granules. Cells were fixed and then DAB stained. Ultrathin sections were analyzed by electron micros-
copy. Two representative images of Ebag9+/+ and Ebag9–/– CTLs are shown. Original magnification, ×2,000. (B) The diameter of each DAB-
stained lytic granule was measured and is expressed as relative frequency distribution. For WT CTLs, 281 lytic granules were examined, and for 
EBAG9-deficient CTLs, 356 lytic granules were examined. Four different animals per group were analyzed (shown are mean values).
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used in generation of the F6 and F8 mouse strains, with identical results. 
In addition, Ebag9–/– mice were backcrossed with OT-I TCR transgenic 
mice and used in generation of the F7 mouse strain. Mice were further 
genotyped using PCR with following primer pairs: 5′-CGCTACCACTGAG-
GATGAGGA-3′ and 5′-GAGAAACCCCATCTAGTTCACATGC-3′ for the 
WT allele; 5′-GGCGCGGTCCCAGGTCCAC-3′ and 5′-GTTTGCCCAGT-
CATAGCCGAATAGCC-3′ for the mutant allele.
Mice. C57BL/6 and BALB/c mice were obtained from Charles River Lab-
oratories. TCR transgenic (CD4+) DO11.10 (H-2d haplotype) and OT-II 
(H-2b haplotype) were bred in our facility and recognized the OVA-derived 
peptide aa 323–339. OT-I mice (CD8+ TCR transgenic mice) recognized the 
OVA-derived cognate peptide SIINFEKL (63). All mice were maintained 
and bred under standard specific pathogen–free conditions. Experimen-
tal animal groups were sex and age matched. Animal experiments were 
reviewed and approved by the Berlin State review board at the Landesamt 
für Gesundheit und Soziales (registered Berlin LaGeTsi 0331/05).
Cell culture, transfection, and lymphocyte activation. Jurkat human T cells and 
P815 cells were cultured in RPMI 1640 medium (PAA Laboratories) with 
10% FCS, penicillin-streptomycin, glutamine, and Na-pyruvate (complete 
RPMI medium). MDA-MB435 cells were transfected using Lipofectamine 
2000 (Invitrogen). Generation of stably transfected MDA-MB435 cell lines 
was done in selection medium containing 700 μg/ml geneticin-sulphate 
(G-418), and stable clones were maintained in the presence of 400 μg/ml 
G-418. Jurkat cells were transfected using an Amaxa electroporation sys-
tem, according to the manufacturer's instructions.
CTLs were derived by activation of 4 × 106 splenocytes/ml from effec-
tor strain C57BL/6 (H-2b haplotype) (Ebag9+/+ and Ebag9–/–) with 4 × 106 
irradiated (3,000 rads) splenocytes/ml as stimulators from BALB/c (H-2d 
haplotype) mice in complete RPMI medium supplemented with β-mer-
captoethanol. After 3–6 days in culture, CTLs were purified over Biocoll 
(Biochrom), washed, and used for cytotoxicity and secretion assays as 
described below. For confocal microscopy analysis, naive CD8+ T cells 
were stimulated by culturing cells for 3–4 days with plate-bound anti-
CD3ε mAb (3 μg/ml) and anti-CD28 mAb (2 μg/ml) in the presence of 
50 U/ml IL-2. CD8+ cells were purified by negative selection with magnetic 
beads (Miltenyi Biotec or Dynal), followed by 1–2 days of culture in the 
presence of IL-2 and IL-7 (Peprotech; 50 U/ml). Purity of CD8+ cells was 
usually greater than 90%. For all functional and biochemical assays, com-
parable activation status of CTLs derived from KO and WT animals were 
confirmed by CD25 or CD69 expression.
NK cells were separated from spleen cells using anti-DX5 mAb–conju-
gated MACS microbeads (Miltenyi Biotec) according to the manufacturer’s 
instructions. DX5+ cells were cultured for 9 days in complete RPMI medi-
um supplemented with IL-2 (1,000 U/ml). Purity was greater than 98%, as 
determined by flow cytometry (NK-1.1+ or CD49b+).
Antibodies. A polyclonal rabbit anti-EBAG9 serum was described previ-
ously (12). Anti-B220–FITC mAb (clone RA3-6B2), anti-CD3ε mAb (clone 
145-2C11), anti-CD3ε–biotin mAb (clone 145-2C11), anti-CD4–FITC mAb 
(clone H129.19), anti-CD8a–APC mAb (clone 53-6.7), anti-CD8a–FITC 
mAb (clone 53-6.7), anti-CD16/32 mAb (clone 2.4G2), anti-CD25–biotin 
mAb (clone 7D4), anti-CD28 mAb (clone 37.51), anti-CD49b (clone DX5), 
anti–NK-1.1 (clone PK136), anti-CTLA4–PE (clone UC10-4F10-11), anti-
GM130 mAb (35), anti–IFN-γ–APC mAb (clone XMG1.2), and anti-Lamp1 
mAb (clone 1D4B) were obtained from BD Biosciences. Polyclonal rabbit 
anti-Snapin, anti-SNAP23, anti–syntaxin 4, anti–syntaxin 7, anti–syntaxin 8, 
and anti–synaptotagmin VII sera were purchased from Synaptic Systems. 
Anti-VAMP7 (clone 1C7) was from Novus Biologicals. Anti–granzyme B, 
anti-granzyme B–Alexa Fluor 647 mAb (clone 16G6), and biotinylated anti-
Figure 13
EBAG9 deletion does not affect formation of the immuno-
logical synapse. (A) CTLs obtained from MLR (day 6–7) 
were mixed with the anti-CD3–coated latex beads and 
incubated for 0, 10, or 30 minutes at 37°C. Conjugates 
were plated on coverslips, fixed, and permeabilized. Per-
forin was stained with a biotinylated anti-perforin antibody. 
Polarization of perforin toward the contact site of CTLs and 
microbeads was assessed by confocal microscopy and 
quantified by random selection of conjugates. Those con-
jugates showing a distinct perforin immunofluorescence at 
the T cell–bead contact site were considered polarized. 
Beads are visible in Brightfield images as opaque round 
structures. One representative image of WT CTLs is 
shown. Scale bars: 5 μm. (B) Bars show statistical analy-
sis from 3 independent experiments with at least 100 cells 
evaluated. Data represent mean ± SD.
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perforin antibody (clone JAW247) were purchased from eBiosciences. Anti-
CD3ε–Alexa Fluor 488 mAb (clone 500A2), anti-CD8a–Alexa Fluor 647 mAb 
(clone 5H10), anti-CD8a–APC (clone CT-CD8a), and KJ1.26-APC were from 
Caltag Laboratories. Polyclonal goat anti–cathepsin D was obtained from 
Santa Cruz Biotechnology Inc. and R&D Systems. Polyclonal rabbit anti-
Lck was from Abcam, biotinylated anti-GFP antibody was purchased from 
Vector Laboratories. Anti-Flag mAb (clone M5) was from Sigma-Aldrich. 
Anti-GFP mAb and anti-HA were from Roche. Cy5-labeled donkey anti-rat 
antibody, Cy5-conjugated donkey anti-chicken antibody, and streptavidin-
Cy5 conjugate were obtained from Jackson ImmunoResearch Laboratories. 
Alexa Fluor 568–conjugated goat anti-rabbit antibody, goat anti-mouse, 
or donkey anti-goat antibodies were from Invitrogen. Appropriate isotype 
controls for flow cytometry were purchased from BD Biosciences or Caltag 
Laboratories. A TM-β1 antibody was provided by T. Schüler (Charité).
In vitro cytotoxicity assay. Cytolytic activity of MLR-derived CTLs against 
allogeneic P815 cells was determined using Cytotox 96 nonradioactive 
kit (Promega) according to the manufacturer’s instructions. Percent lysis 
was calculated as 100 × (experimental – effectorspontaneous – targetspontaneous 
/ effectormaximum – targetspontaneous). Cytotoxicity assays were performed in 
quadruplicate and were repeated at least 8 times. Cytolytic activity of NK 
cells against YAC-1 cells was determined as described above. Values for tar-
get cell lysis are the mean ± SD of quadruplicates.
In vivo cytotoxicity assay. To investigate CD8+ T cell responses, splenocytes 
from C57BL/6 mice (1 × 107 cells/ml PBS) were loaded with 1 μM Tag 
peptide IV (VVYDFLKL; Biosyntan) or left without peptide for 15 minutes 
at 37°C. Cells were washed twice and labeled with different amounts of 
CFSE for 15 minutes at 20°C: 1 μM for the peptide-loaded population 
(CFSEhigh) and 0.1 μM for non-loaded population (CFSElow). Subsequently, 
Figure 14
EBAG9 controls targeting of lysosomal marker molecules toward the secretory lysosome compartment. Representative immunofluorescence 
images of Ebag9+/+ and Ebag9–/– CTLs, activated by incubation on anti-CD3e/anti-CD28–coated culture plates (day 4–5). CD8+ cells were puri-
fied by negative selection with magnetic beads. Colocalization between the indicated proteins was quantified by calculating r. Image sets to 
be compared between WT and KO samples were acquired during the same session using the same acquisition settings. Dots of granzyme B 
or Lamp1 immunofluorescence were randomly selected and set as regions of interest. In this figure legend, n indicates the number of vesicles 
analyzed in at least 3 independent experiments. (A) Colocalization of granzyme B with the lysosomal marker cathepsin D. Ebag9+/+, mean 
r = 0.059 (n = 179); Ebag9–/–, mean r = 0.182 (n = 196). The difference between Ebag9+/+ and Ebag9–/– mice was statistically significant 
(P < 0.0001, Student’s t test). Scale bar: 10 μm. (B) Colocalization of Lamp1 with cathepsin D. Ebag9+/+, mean r = 0.352 (n = 475); Ebag9–/–, 
mean r = 0.176 (n = 367). The difference between Ebag9+/+ and Ebag9–/– mice was statistically significant (P < 0.0001, Student’s t test). Colocal-
ization is expressed as relative frequency distribution, whereby r was plotted against the frequency of vesicles counted for 1 class of r values.
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cells were washed in complete RPMI medium and twice in PBS. In primary 
CTL responses, target cells (2 × 107) at a 1:1 ratio were injected i.v. on day 7 
into mice that had been previously immunized (s.c. or i.p., on day 0) 
with the Tag-bearing tumor cell line Co16.113. After 4 hours, spleens of 
recipient mice were analyzed by flow cytometry. The specific cytolytic 
activity was calculated as 100 × (% of CFSEhigh cells / % of CFSElow cells) 
(32). NK cell activity was analyzed by monitoring lysis of H-2d–allogeneic 
splenocytes according to the procedure described above. Briefly, spleno-
cytes from BALB/c mice (H-2d haplotype) and C57BL/6 (H-2b haplotype) 
were labeled with different amounts of CFSE and injected at a 1:1 ratio 
(i.v.) into Ebag9+/+ and Ebag9–/– mice. After 4 hours, recipient splenocytes 
were analyzed by flow cytometry for the relative survival of the donor 
allogeneic population (64).
Antigen-specific T cell proliferation assay. Bone marrow–derived DCs were 
generated essentially as previously described (65, 66). After 8–9 days of 
culture, DCs were harvested and incubated either overnight with OVA 
protein (Sigma-Aldrich) including 0.1–1 μg/ml LPS or for 2 hours with 
OVA-derived peptide (aa 323–339). In some cases, DCs were stored frozen 
in liquid nitrogen prior to their usage. Equal quality of the DC prepara-
tion obtained from Ebag9+/+ and Ebag9–/– mice was always assessed by flow 
cytometry using anti-CD11c, CD86, and MHC class II antibodies. For 
each in vitro proliferation experiment, DCs were matched according to 
these maturation markers. To obtain responder T cells, T cells from TCR 
transgenic mice were isolated from splenocytes by negative selection using 
appropriate combinations of anti-B220, anti-CD8, or anti-CD4 Dyna-
beads (Dynal) according to the manufacturer’s instructions, followed by 
Figure 15
EBAG9 controls intracellular sorting and processing of cathepsin D. (A and B) CTLs were pulse-labeled with 500 μCi [35S]methionine/cysteine for 
15 minutes and chased for 0 minutes (A) and 100 minutes (B). A postnuclear supernatant was enriched for a light microsomal fraction, including 
lysosomes by centrifugation at 20,000 g for 20 minutes. Pellets were further resolved on a continuous OptiPrep gradient. Fractions (0.9 ml) were 
collected from the top of each gradient and lysed in an equal volume of 2× NP-40 lysis buffer, and aliquots were immunoprecipitated with a mix-
ture of anti–cathepsin D antibodies. Samples were analyzed by SDS-PAGE. Aliquots of each fraction were precipitated with TCA and analyzed 
by immunoblot using a polyclonal anti–granzyme B serum. Data are representative of 2 experiments performed, with pooled CTLs from 6 mice 
per group. (C) Distribution of radioactivity along the gradients is shown.
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CFSE labeling. On average, more than 85% pure TCR transgenic T cells 
were recovered and used for in vitro proliferation. In the coculture system, 
1 × 105 CFSE-labeled T cells were mixed with 1 × 104 DCs in round-bottom, 
96-well tissue culture plates for the times indicated in Figure 5 (65).
Cell transfer experiments. CD8+ and CD4+ spleen cells from OT-I, OT-II, or 
DO11.10 TCR transgenic mice were purified by negative selection applying 
magnetic cell sorting (MACS; Miltenyi Biotec), according to the manufac-
turer’s instructions. Usually, purity of isolated naive transgenic T cells was 
greater than 90% (CD62Lhigh). CFSE-labeled TCR transgenic T cells were 
adoptively transferred i.v. in Ebag9+/+ or Ebag9–/– recipient animals. Alterna-
tively, OT-I/Ebag9+/+ and OT-I/Ebag9–/– CD8+Vα2 T cells (CD45.2 congenic 
mouse strain) were injected i.v. into congenic C57BL/6/LY-5.1 (CD45.1 
congenic mouse strain) recipients. One day after adoptive transfer, mice 
were immunized i.v. or s.c. with OVA protein and CpGs, as specified in the 
figure legends. To determine proliferation of adoptively transferred T cells, 
mice were sacrificed 2–3 days after immunization. Splenocytes or inguinal 
lymph node cells were prepared, and cells were stained with anti-clonotypic 
TCR or anti-CD45.2, -CD4, or -CD8 antibodies. CFSE dilution was deter-
mined by flow cytometry using a FACSCalibur or a FACSCanto II cytom-
eter with CellQuest or FACSDiva and FloJo software, respectively (BD Bio-
sciences). Figures were assembled in FreeHand 10 software (Adobe).
H-2Kb:Ig dimer staining, intracellular IFN-γ staining and flow cytometric analysis. 
Single-cell suspensions of spleen cells were prepared and restimulated for 
4 days at 2 × 106 cells/ml with 1 μg/ml Tag epitope IV peptide in complete 
RPMI medium supplemented with 10 U/ml IL-2, essentially as previously 
described (32). For dimer staining, cells were incubated for 1 hour with 
Tag peptide–loaded H-2Kb:Ig dimers (BD Biosciences) and PE-labeled anti-
mouse IgG1 secondary antibody according to the manufacturer’s instruc-
tions. Cells were stained simultaneously with APC-conjugated anti-CD8a 
mAb. For intracellular IFN-γ staining, cells were restimulated for 4 hours 
with 1 μg/ml Tag peptide in the presence of Golgi-Plug (1:1,000; BD Biosci-
ences). Then, cells were prepared and stained as previously described (67). 
Analysis was performed by flow cytometry.
L. monocytogenes infection. Mice were infected with the L. monocytogenes 
strain EGD essentially as previously described (67). Briefly, 5 × 103 bacteria 
in a volume of 200 μl PBS were injected into a lateral tail vein. For deter-
mination of bacterial burdens in liver, mice were killed, livers were homog-
enized in PBS, serial dilutions of homogenates were plated on PALCAM 
agar supplemented with selective antibiotics (Merck), and colonies were 
counted after 48 hours of incubation at 30°C.
Yeast 2-hybrid screen. A full-length human EBAG9 cDNA was used for 
screening a human lymph node cDNA library (BD Biosciences) expressed 
in AH109 yeast cells according to the MATCHMAKER GAL4 2-hybrid sys-
tem 3 (BD Biosciences), essentially as previously described (12).
Plasmids, GST pulldown assays, coimmunoprecipitation, SDS-PAGE, and immu-
noblotting. Human γ2-adaptin–HA plasmid was provided by K. Nakayama 
(University of Tsukuba, Tsukuba, Japan) (7), and the GST-fusion constructs 
of γ1- and γ2-adaptin (68) were a donation from J.S. Bonifacino (National 
Institute of Child Health and Human Development, Bethesda, Maryland, 
USA). For GST fusion protein pulldown assays, cell extracts were prepared 
from transfected Jurkat or MDA-MB435 cells by using Triton X-100–con-
taining lysis buffer (0.5% Triton X-100, 50 mM Tris-HCl, pH 7.4, 50 mM 
NaCl, 1 mM MgCl2). Then, cell lysates from 2 × 106 cells were incubated 
with 8 μg of GST fusion protein immobilized on glutathione–Sepharose 
4B beads. Beads were washed extensively with the same buffer, and bound 
protein was analyzed by SDS-PAGE. For coimmunoprecipitation stud-
ies, stably transfected MDA-MB435 or transiently transfected Jurkat cells 
(1 × 107 cells) were solubilized in Triton X-100–containing lysis buffer (see 
above). Immunoprecipitation, gel electrophoresis, and immunoblotting 
were performed essentially as previously described (12). CTL lysates from 
equal number of cells for quantitation of SNARE molecules were generated 
in RIPA buffer (total number of mice was 9 per group).
Subcellular fractionation. To resolve the distribution of endosomal-lyso-
somal SNARE molecules, 8 × 107 to 1 × 108 CTLs (days 6–7) were resus-
pended in 1.5 ml of homogenization buffer (10 mM Tris-HCl, pH 7.4, 250 
mM sucrose, 1 mM EDTA, 0.2 mM PMSF, Roche protease inhibitor tab-
lets) and homogenized on ice with 20 strokes of a Dounce homogenizer 
with a tight-fitting pestle. A postnuclear supernatant was centrifuged for 
45 minutes at 100,000 g to sediment the microsomal fraction. Pellets were 
resolubilized in homogenization buffer and loaded on a continuous pre-
formed 10%–30% OptiPrep gradient (Axis-Shield). The gradient was cen-
trifuged in a SW-40 rotor at 185,000 g for 3 hours. Fractions were taken 
from the top, and protein was precipitated with TCA and further analyzed 
by immunoblotting.
Metabolic labeling, subcellular fractionation and pulse-chase analysis of cathepsin D. 
Metabolic labeling of day 6–7 CTLs (8 × 107 to 1 × 108) was done as pre-
viously described (12). Cells were suspended in 1.5 ml of homogeniza-
tion buffer (10 mM Tris-HCl, pH 7.4, 250 mM sucrose, 1 mM EDTA, 
0.2 mM PMSF, Roche protease inhibitor tablets) and homogenized on 
ice with 20 strokes of a Dounce homogenizer with a tight-fitting pestle. 
A postnuclear supernatant was centrifuged for 20 minutes at 20,000 g to 
enrich a light mitochondrial and lysosomal fraction. Pellets were resolu-
bilized in homogenization buffer and loaded on a continuous preformed 
10%–30% OptiPrep gradient. The gradient was centrifuged in a SW-40 rotor 
at 52,000 g for 14 hours. Fractions were taken from the top, and an equal 
volume of 2× NP-40 lysis buffer was added. Distribution of radioactivity 
was determined using liquid spectrometry after TCA precipitation.
Secretion assay. CTLs (1 × 105 cells/well; 100 μl/well) derived from MLR were 
cultured in round-bottom 96-well plates coated with anti-CD3ε mAb (5 μg/
ml), or in plates left uncoated. After 4 hours, plates were centrifuged and cell 
supernatant was assayed for granzyme A activity as described previously (38).
Immunological synapse formation. Polybead carboxylate latex microspheres 
(6 μM) were coated with 5 μg anti-CD3 mAb according to the manufac-
turer’s instructions (Polysciences). In some experiments, Dynabeads 
(4.5 μm) precoated with CD3/CD28 antibodies (Invitrogen) were used 
instead (Supplemental Figures 6 and 7). CTLs were mixed with the anti-
CD3–coated latex beads, centrifuged at low speed (380 g), and incubated 
for 5 minutes at 37°C in RPMI without FCS, allowing the formation of 
conjugates. Subsequently, cells were resuspended in complete RPMI medi-
um and incubated for the indicated times at 37°C. Next, conjugates were 
plated on poly-L-lysine–coated coverslips, fixed in either acetone or 4% 
PFA, permeabilized, and stained with a biotinylated anti-perforin antibody 
and streptavidin–Alexa Fluor 568 conjugate (Invitrogen).
Generation of retroviral vectors and transduction of T cells. To generate pMP71-
mEG, the murine EBAG9 cDNA coding sequence was amplified by PCR from 
total murine cDNA and cloned into the single Not-I site of pMP71GPRE, 
thereby creating a mEBAG9-GFP fusion protein. Ecotropic packaging cells 
GP+E86 were cotransfected with the retroviral vector plasmid pMP71-mEG 
and pWLneo (Stratagene) to generate ecotropic vector particle–producing 
cells. Single-cell suspensions of spleens from OVA-specific TCR transgenic 
(OT-1) C57BL/6 mice were prepared and cultured (2 × 106/ml) for 24 hours 
in the presence of 1 μg/ml chicken OVA257–264 (SIINFEKL) peptide (Biosyn-
tan) and 10 U/ml IL-2. Stimulated cells were transduced on 2 consecutive 
days in RetroNectin-coated plates (Takara) (69).
Electron microscopy. CTLs were labeled overnight with 2 mg/ml horse-
radish peroxidase (Serva) in complete RPMI medium. Cells were washed 
3 times with PBS and fixed in 2% formaldehyde/1% glutaraldehyde for 
60 minutes on ice, followed by DAB staining. Lymphocytes were refixed 
with 2% formaldehyde/1.5% glutaraldehyde in 0.1 M cacodylate buffer for 
2 hours and treated with 1% osmium tetroxide/1.5% potassium ferro-
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cyanide in 0.1 M cacodylate buffer for 2 hours. Samples were dehydrated 
through a graded series of ethanols and embedded in Poly/Bed 812 (Poly-
sciences). Ultrathin sections were stained with uranyl acetate for 3 minutes 
and examined with a Zeiss EM 910. Digital images were taken with a 1kx1k 
high-speed slow-scan CCD camera (Proscan) and analySIS 3.2 software.
Confocal image acquisition and correlation analysis. Activated T cells were 
grown for at least 4 hours on fibronectin-coated coverslips (Sigma-
Aldrich). For activation of the TCR, coverslips were either left untreated 
or additionally coated with anti-CD3ε mAb (5 μg/ml) and anti-CD28 mAb 
(3 μg/ml). Cells were rinsed in PBS and fixed in –20°C acetone for 5 minutes, 
followed by permeabilization with PBS containing 0.05% Triton X-100 for 
5 minutes. Next, cells were stained for 2 hours with the antibodies indicated 
in Figures 7, 8, and 14 (1:100 in PBS with 5% BSA). Bound antibodies were 
detected with Alexa Fluor 568– or Cy5-conjugated secondary antibodies. 
Images were acquired with a Zeiss LSM510Meta confocal setup on an Axio-
vert 200 M inverted microscope equipped with a 3-line laser. Digital images 
were collected using a ×63 phase contrast plan–apochromat oil objective 
NA 1.4 or a ×100 DIC oil objective. For all acquisition settings, the main 
beam splitter was HFT UV/488/453/633, with following parameters for 
each fluorochrome: FITC and GFP, 488 nm (light wavelength excitation 
[λexc]) and BP500–530 nm (light wavelength emission [λem]); Alexa Fluor 
568, 543 nm (λexc) and BP565–615IR (λem); Cy5 and Alexa Fluor 647, 633 
nm (λexc) and LP650 nm (λem). The image acquisition was done sequentially 
(multi-track) to minimize potential cross-talk between the fluorophores, 
and images were processed using LSM Examiner 3.2 and LSM Browser soft-
ware (Zeiss). To better visualize colocalization of proteins, the Cy5/Alexa 
Fluor 647 were reassigned to green or red colors.
Colocalization was quantified by calculating the Pearson’s correlation 
coefficient (r), according to the following formula (Ch, channel; values are 
pixel intensities):
       (Equation 1)
Individual dots were marked as regions of interest using the LSM soft-
ware, essentially as previously described (57). For each region of interest the 
software calculated r. Maximal r values (rmax) were calculated for EBAG9-
GFP and anti-GFP staining, followed by detection with a Cy5-conjugated 
secondary antibody. Minimal r values (rmin) were determined for GM130 
and CD8a staining. In all experiments the intensity of signals was kept 
equal. r was plotted against the frequency of vesicles counted for 1 class 
of r values. The Pearson’s correlation coefficient takes into consideration 
similarities between shapes, while ignoring the intensities of signals, and 
thus is applicable when fluorescence intensities are equal (70). Thus, for 
each experiment comparing WT and gene-deleted mice, average signal 
intensities between fluorescence detection channels were calculated and 
showed no significant differences. In addition, in each individual confocal 
microscopy analysis, average pixel intensities (channel 1 or 2) obtained for 
Ebag9+/+ and Ebag9–/– CTLs showed indistinguishable values. In agreement 
with Zinchuk et al. (71) and based on the rmax and rmin values determined, 
r values greater than 0.5 were considered as good colocalization. All figures 
were assembled with Corel Draw (Corel).
Statistics. Results are expressed as mean ± SD or SEM. Data were con-
sidered statistically significant for P ≤ 0.05, which was determined using 
the 2-tailed unpaired Student’s t test or the Mann-Whitney U test, where 
appropriate. The 1-way ANOVA test was used for the calculation of fre-
quency distributions in electron microscopy images.
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